PL3174891T3 - Krystaliczna postać rybozydu nikotynamidu - Google Patents

Krystaliczna postać rybozydu nikotynamidu

Info

Publication number
PL3174891T3
PL3174891T3 PL15825253T PL15825253T PL3174891T3 PL 3174891 T3 PL3174891 T3 PL 3174891T3 PL 15825253 T PL15825253 T PL 15825253T PL 15825253 T PL15825253 T PL 15825253T PL 3174891 T3 PL3174891 T3 PL 3174891T3
Authority
PL
Poland
Prior art keywords
crystalline form
nicotinamide riboside
riboside
nicotinamide
crystalline
Prior art date
Application number
PL15825253T
Other languages
English (en)
Inventor
Erik C. Carlson
Michael C. Standen
Westin M. Morrill
Original Assignee
W.R. Grace & Co. - Conn.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55163976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3174891(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by W.R. Grace & Co. - Conn. filed Critical W.R. Grace & Co. - Conn.
Publication of PL3174891T3 publication Critical patent/PL3174891T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL15825253T 2014-07-24 2015-07-24 Krystaliczna postać rybozydu nikotynamidu PL3174891T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462028702P 2014-07-24 2014-07-24
EP15825253.6A EP3174891B1 (en) 2014-07-24 2015-07-24 Crystalline form of nicotinamide riboside
PCT/US2015/041956 WO2016014927A2 (en) 2014-07-24 2015-07-24 Crystalline form of nicotinamide riboside

Publications (1)

Publication Number Publication Date
PL3174891T3 true PL3174891T3 (pl) 2020-08-10

Family

ID=55163976

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20153772T PL3670522T3 (pl) 2014-07-24 2015-07-24 Krystaliczna postać chlorku rybozydu nikotynamidu
PL15825253T PL3174891T3 (pl) 2014-07-24 2015-07-24 Krystaliczna postać rybozydu nikotynamidu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL20153772T PL3670522T3 (pl) 2014-07-24 2015-07-24 Krystaliczna postać chlorku rybozydu nikotynamidu

Country Status (7)

Country Link
US (2) US10323058B2 (pl)
EP (2) EP3670522B1 (pl)
CN (1) CN106715454B (pl)
CA (1) CA2956163C (pl)
ES (2) ES2776395T3 (pl)
PL (2) PL3670522T3 (pl)
WO (1) WO2016014927A2 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2963057T3 (es) * 2015-03-09 2024-03-25 Grace W R & Co Forma cristalina de ribósido de nicotinamida
KR102354784B1 (ko) 2015-08-05 2022-01-25 메트로 인터내셔널 바이오테크 엘엘씨 니코틴아미드 모노뉴클레오티드 유도체 및 그 용도
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
CA3017254C (en) 2016-03-16 2023-08-22 ChromaDex Inc. B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
WO2017218580A1 (en) 2016-06-14 2017-12-21 Rejuvenation Therapeutics Corporation Synthetic methods for the preparation of nicotinamide riboside and related compounds
NZ803738A (en) 2016-11-11 2024-05-31 Chromadex Inc Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
JP7136795B2 (ja) 2016-11-29 2022-09-13 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 母体の健康および／または子の健康を向上させるためのｎａｄ前駆体の使用
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
WO2018236814A2 (en) 2017-06-19 2018-12-27 Gangadhara Ganapati NICOTINAMIDE RIBOSID DERIVATIVES AND USES THEREOF
JP2021506898A (ja) * 2017-12-22 2021-02-22 エリシウム ヘルス，インコーポレーテッド ニコチンアミドリボシドクロリドの結晶形態
AU2019214858B2 (en) 2018-01-30 2023-02-02 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
WO2019219895A1 (en) 2018-05-18 2019-11-21 Roche Diagnostics Gmbh (thio)nicotinamide ribofuranoside salts and compositions, methods of making, and uses thereof
CN108774278A (zh) * 2018-09-10 2018-11-09 张洪喜 一种制备尼克酰胺核苷盐的方法
CN113301898B (zh) * 2018-12-10 2022-11-18 可劳迈戴斯有限公司 烟酰核苷及其衍生物的晶型，及其制备方法
EP3897666A2 (en) 2018-12-17 2021-10-27 Mitopower LLC Nicotinyl riboside compounds and their uses
WO2020172629A1 (en) * 2019-02-21 2020-08-27 ChromaDex Inc. Use of nicotinamide riboside, nicotinic acid riboside, reduced nicotinyl riboside compounds, and nicotinyl riboside compound derivatives in formulations
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
IL289941B2 (en) 2019-07-19 2025-07-01 Biosynth Ag Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof
CN111808156A (zh) * 2020-07-15 2020-10-23 许昌远志生物科技有限公司 一种β-烟酰胺核糖氯化物的晶型1A、晶型1B及其制备方法
WO2022058312A1 (en) * 2020-09-15 2022-03-24 Société des Produits Nestlé S.A. Methods for producing dihydronicotinamide riboside from nicotinamide riboside chloride
MX2023013903A (es) 2021-05-27 2023-12-11 Metro Int Biotech Llc Solidos cristalinos de mononucleotido de acido nicotinico y esteres de estos y metodos de elaboracion y uso.

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1190080A (en) 1966-08-08 1970-04-29 Kyowa Hakko Kogyo Company Ltd Process for producing Nicotinamide Adenine Dinucleotide
US3728111A (en) 1971-09-21 1973-04-17 Asea Ab Method of manufacturing billets from powder
EP0981534B1 (en) 1997-02-06 2006-05-03 Inspire Pharmaceuticals, Inc. Dinucleotides and their uses
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
EP1366055A2 (en) 2000-12-15 2003-12-03 Pharmasset Limited Antiviral agents for treatment of flaviviridae infections
US7179791B2 (en) 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20050020587A1 (en) 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US8114626B2 (en) 2004-02-10 2012-02-14 Trustees Of Dartmouth College Yeast strain and method for using the same to produce nicotinamide riboside
CA2555675A1 (en) 2004-02-10 2005-08-25 Trustees Of Dartmouth College Nicotinamide riboside kinase compositions and methods for using the same
US7776326B2 (en) 2004-06-04 2010-08-17 Washington University Methods and compositions for treating neuropathies
ES2430569T3 (es) 2005-02-18 2013-11-21 Astrazeneca Ab Compuestos antibacterianos derivados de piperidina
CA2610854A1 (en) * 2005-03-30 2006-10-05 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20070149466A1 (en) 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
DK1957086T3 (en) 2005-11-18 2018-06-06 Cornell Res Foundation Inc NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE
AU2006339607A1 (en) 2005-12-02 2007-09-13 Sirtris Pharmaceuticals, Inc. Modulators of Cdc2-like kinases (Clks) and methods of use thereof
WO2007136744A1 (en) 2006-05-19 2007-11-29 The Johns Hopkins University Crystal structure of a substrate complex of nampt/pbef/visfatin
JP2010513458A (ja) 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用
CA2676609A1 (en) 2007-01-26 2008-07-31 Washington University Methods and compositions for treating neuropathies
CA2725481A1 (en) * 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
US20100015072A1 (en) 2008-06-30 2010-01-21 Christopher Polla Topical Compositions Comprising Isonicotinamide
US20100035354A1 (en) 2008-08-06 2010-02-11 Ettore Bigatti Process for preparing azacytidine intermediate
US20120164670A1 (en) 2009-06-23 2012-06-28 President And Fellows Of Harvard College Methods and kits for measuring enzyme activity
MX364173B (es) 2009-07-24 2019-04-15 Amazentis Sa Star Compuestos, composiciones y metodos para proteger la salud cerebral en trastornos neurodegenerativos.
US8507251B2 (en) 2009-09-28 2013-08-13 Robert J. Greenstein Medium and method for culturing Mycobacterium avium subspecies paratuberculosis
US9603862B2 (en) * 2009-12-14 2017-03-28 Cornell University Activation and activators of SIRT5
US20130165398A1 (en) 2010-03-29 2013-06-27 Paul Hochegger Concentration-enhancing drink
WO2012004917A1 (ja) 2010-07-06 2012-01-12 Kaminishi Hidenori 神経突起伸長剤
US20140065099A1 (en) 2011-02-15 2014-03-06 Ecole Polytechnique Federale De Lausanne (Epfl) Methods of Treating Mitochondrial Dysfunction
US20120107888A1 (en) 2011-02-17 2012-05-03 Qteros, Inc. Modulation of fermentation products through vitamin supplementation
US20120328526A1 (en) 2011-06-27 2012-12-27 University Of Maryland, Baltimore Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof
CA2847292A1 (en) 2011-06-29 2013-01-03 The General Hospital Corporation Compositions and methods for enhancing bioenergetic status in female germ cells
EP3345901A3 (en) 2011-06-29 2018-09-12 President and Fellows of Harvard College Small molecules as antiaging agents
US20140045874A1 (en) 2012-07-09 2014-02-13 Noglo Llc Prevention of alcohol reaction with dietary supplements
US20140256760A1 (en) 2012-07-09 2014-09-11 Noglo Llc Reduction or prevention of alcohol reaction with dietary supplements
ES2785303T3 (es) 2012-07-16 2020-10-06 Univ Cornell Nicotinamida ribósido para tratar la pérdida auditiva
AU2013329312A1 (en) 2012-10-09 2015-05-28 Massachusetts Institute Of Technology Treatment of age-related and mitochondrial diseases by inhibition of HIF-1 alpha function
WO2014111906A1 (en) 2013-01-21 2014-07-24 Ecole Polytechnique Federale De Lausanne (Epfl) Bioluminescence imaging of small biomolecules
CA2902879C (en) 2013-03-15 2023-09-26 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
GB201313465D0 (en) * 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
EP3060311B1 (en) 2013-10-24 2019-05-22 The Procter and Gamble Company Skin lightening cosmetic compositions and methods
KR20150050406A (ko) 2013-10-29 2015-05-08 한림대학교 산학협력단 니코틴아마이드 라이보사이드를 유효성분으로 포함하는 패혈증 치료 또는 예방용 약제학적 조성물
KR20160067195A (ko) 2013-10-30 2016-06-13 크로마덱스 아이엔씨. 피부 질환 치료에서의 국소적 사용을 위한 니코틴아미드 리보사이드 조성물
CN105992521A (zh) 2013-11-12 2016-10-05 奥索努特拉有限责任公司 基于特咖宁的补充剂及其使用方法
WO2015099842A1 (en) 2013-12-23 2015-07-02 Abbott Laboratories Hot beverage fortifier
AU2015229055B2 (en) 2014-03-13 2019-09-12 Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
JP2017510572A (ja) 2014-03-13 2017-04-13 ソーク インスティチュート フォー バイオロジカル スタディーズ Ｆｘｒアゴニストならびに作製および使用のための方法
US20150297508A1 (en) 2014-04-21 2015-10-22 William Andriette Topical Formulation to Enhance Genital Sensation and Function
EP3149016A1 (en) * 2014-06-02 2017-04-05 Glaxosmithkline Intellectual Property (No. 2) Limited Preparation and use of crystalline beta-d-nicotinamide riboside
AU2015270090A1 (en) 2014-06-06 2016-12-22 Glaxosmithkline Intellectual Property (No.2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
JP2017522314A (ja) 2014-07-17 2017-08-10 ザ スクリプス リサーチ インスティテュート がん治療を向上させるための方法および組成物
ES2963057T3 (es) * 2015-03-09 2024-03-25 Grace W R & Co Forma cristalina de ribósido de nicotinamida

Also Published As

Publication number Publication date
EP3174891A4 (en) 2018-05-30
US10323058B2 (en) 2019-06-18
PL3670522T3 (pl) 2022-02-21
WO2016014927A2 (en) 2016-01-28
CA2956163C (en) 2023-01-10
CN106715454B (zh) 2020-06-16
CA2956163A1 (en) 2016-01-28
ES2776395T3 (es) 2020-07-30
ES2908332T3 (es) 2022-04-28
EP3670522B1 (en) 2022-01-19
CN106715454A (zh) 2017-05-24
EP3174891B1 (en) 2020-01-29
US10233207B2 (en) 2019-03-19
EP3670522A1 (en) 2020-06-24
US20180086783A1 (en) 2018-03-29
EP3174891A2 (en) 2017-06-07
WO2016014927A3 (en) 2016-09-15
US20170210774A1 (en) 2017-07-27

Similar Documents

Publication Publication Date Title
ZA201705776B (en) Crystalline form of nicotinamide riboside
PL3174891T3 (pl) Krystaliczna postać rybozydu nikotynamidu
IL251560A0 (en) Methods for preparing ribosides
EP3136857A4 (en) Crystalline form of baricitinib
SG10201913200XA (en) Crystalline form of lorlatinib free base
IL246385B (en) Crystalline forms of efitinib di-malate
SI3845221T1 (sl) Trdne oblike sofosbuvirja
SI3380554T2 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
PL3113773T3 (pl) Krystaliczne postaci grapiprantu
SG10202101979TA (en) Crystalline forms of c21h22ci2n4o2
IL246979A0 (en) Crystalline forms of sofosbuvir
PL3529236T4 (pl) Krystaliczne formy erawacykliny
IL251863A0 (en) Crystalline forms of ferric-maltol
EP3207034A4 (en) Anhydrous crystalline form of s-equol
IL253479A0 (en) Crystalline forms of efinconazole
PL3350179T3 (pl) Krystaliczne postacie
HUP1500506A2 (en) Salts of palbociclib
IL249332A0 (en) Crystalline forms of sofosbuvir